Clicky

Acerus Pharmaceuticals Corporation(ASP)

Description: Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men's and women's health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; Estrace, an oral tablet for the symptomatic relief of menopausal symptoms; and UriVarx, a natural health product that helps reduce symptoms of hyperactive bladder, such as daytime urinary frequency, urgency, and nocturia. It also engages in developing Lidbree, a short acting lidocaine formulation delivered through a proprietary device into the vaginal mucosal tissue; Stendra, a PDE5 inhibitor for the treatment of erectile dysfunction; Elegant vaginal moisturizer, which provides comfort to women suffering from vaginal dryness; and Elegant pH, a pH balanced vaginal product; Gynoflor, an ultra-low dose vaginal estrogen combined with a probiotic for the treatment of vaginal atrophy, restoration of vaginal flora, and treatment of certain vaginal infections; and Tefina, a clinical stage product for women with female sexual dysfunction. In addition, the company provides TriVair technology platform that offer applications for pulmonary and nasal pharmaceutical medications. Acerus Pharmaceuticals Corporation sells products through its salesforce in the United States; and through a network of distributors internationally. The company was formerly known as Trimel Pharmaceuticals Corporation and changed its name to Acerus Pharmaceuticals Corporation in September 2015. Acerus Pharmaceuticals Corporation was founded in 2008 and is headquartered in Mississauga, Canada.


Keywords: Pharmaceutical Cement Pharmaceutical Products Medication Clinic Infection Pharma Probiotic Erectile Dysfunction Human Reproduction Vagina Phenols Gynaecology Sexual Reproduction Natural Health Product Sexual Dysfunction Lidocaine Mississauga Treatment Of Erectile Dysfunction Estranes Testosterone Replacement Therapy Hypogonadism Estradiol Female Sexual Dysfunction Cgmp Specific Phosphodiesterase Type 5 Clinical Stage Product Balanced Vaginal Product Certain Vaginal Infections Estrace Natesto

Home Page: www.aceruspharma.com

ASP Technical Analysis

7025 Langer Drive
Mississauga, ON L5N 0E8
Canada
Phone: 416 679 0771


Officers

Name Title
Mr. Edward Gudaitis Pres, CEO & Director
Mr. Gavin Damstra Sr. VP of International Commercial
Dr. Christopher Sorli F.A.C.E., M.D., Ph.D. Chief Medical Officer
Mr. Kevin Thomas Hickey Sr. VP of US Commercial
Mr. Naveed Manzoor Interim Chief Financial Officer
Mr. Chris Witty Investor Relations
Mr. Philippe Savard Sr. VP, Gen. Counsel & Corp. Sec.
Mr. Hubert Tomasz Czerwinski Pres of Acerus Pharmaceuticals SRL

Exchange: TO

Country: CA

Currency: Canadian Dollar (C$)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 18.0612
Price-to-Sales TTM: 2.5879
IPO Date:
Fiscal Year End: December
Full Time Employees: 14
Back to stocks